微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Neoadjuvant chemotherapy
Neoadjuvant chemotherapy

肿瘤

关键词肿瘤 治疗方法 疾病治疗

词汇介绍

拓展阅读

解析

Neoadjuvant 

       n. 新辅助疗法

       Objective To evaluate the clinical significance of sentinel lymph nodes biopsy (SLNB) in breast cancer patients after neoadjuvant chemotherapy. 目的研究乳腺癌新辅助化疗后前哨淋巴结活检(SLNB)的可行性和效果。

 

Chemotherapy   英 /,kiːmə(ʊ)'θerəpɪ; ,kem-/   美 /,kimo'θɛrəpi/

       n. [临床] 化学疗法

同根词   chemotherapeutic adj. 化学疗法的;chemistry n. 化学;化学过程;chemist n. 化学家;药剂师;chemiluminescence n. [化学] 化学发光,化合光;chemisorption n. [化学] 化学吸收作用;chemoreceptor n. 化学受体;[生理] 化学感受器(等于chemoceptor);chemisorb vt. 用化学方法吸收;用化学方法吸附

       Only half of people who have SCLC survive for four months without chemotherapy. 只有一半的小细胞肺癌患者在没有化疗的情况下,存活了四个月。

概述

在肿瘤和癌症的治疗中我们常说治疗方法,手术、放疗和化疗中的化疗主要是指术后辅助化疗。新辅助化疗是指手术前进行的全身化疗,主要目的为缩小肿块、杀灭转移细胞,以保证后续手术顺利开展。有些病人在手术前发现肿块比较大或者很难切除,这时直接手术可能会导致不能顺利完成,所以推荐病人在术前先进行化疗再手术,这就是新辅助化疗,经过新辅助化疗后瘤体变小,再通过手术切除或者放疗治疗肿瘤。目前已成为许多实体肿瘤多学科治疗体系中的一个重要组成部分。 适应症新辅助化疗在各种肿瘤中都有不同的适应症,一般早期患

Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers复制标题

三阴性和HER2-positive早期乳腺癌治疗测序框架的改变

发表时间:2019-07-01

影响因子:35.4

作者: Lajos Pusztai

期刊:Lancet Oncol.

Important results are emerging from clinical trials showing that surgery followed by chemotherapy might not be the optimal strategy to maximise a patient's chance of survival from triple-negative or HER2-positive breast cancers. Administering chemotherapy before surgery provides an opportunity to directly observe the efficacy of a particular chemotherapy regimen. Patients who have extensive residual invasive cancer after neoadjuvant chemotherapy are at a high risk of recurrence for metastatic disease, which, in turn, make these patients ideal candidates for clinical trials. Two important clinical trials, CREATE-X (UMIN000000843) and KATHERINE (NCT01772472), have shown improved disease-free survival with postoperative capecitabine and ado-trastuzumab emtansine in patients with either triple-negative or HER2-positive breast cancer who had residual disease after neoadjuvant chemotherapy. The opportunity for residual-disease guided therapy, as observed in these trials, is lost when patients undergo surgery first.  In this Personal View, we discuss the clinical implications of the CREATE-X and KATHERINE trials and place them into context with other developments in the adjuvant setting of early-stage breast cancer.

译文

临床试验中出现的重要结果显示,接受化疗的手术可能不是最大化患者三阴性或HER2阳性乳腺癌生存机会的最佳策略。在手术前施用化学疗法提供了直接观察特定化疗方案的功效的机会。在新辅助化疗后患有广泛残留侵袭性癌症的患者转移性疾病复发的风险很高,这反过来使这些患者成为临床试验的理想候选者。两项重要的临床试验,CREATE-X(UMIN000000843)和KATHERINE(NCT01772472),在患有三阴性或HER2阳性乳腺癌且患有残留疾病的患者中,术后使用卡培他滨和ado-trastuzumab emtansine,无病生存率得到改善。新辅助化疗。如果在这些试验中观察到,残留疾病引导治疗的机会在患者首先接受手术时就会丢失。在这个个人观点中,我们讨论了CREATE-X和KATHERINE试验的临床意义,并将它们与早期乳腺癌辅助治疗的其他发展联系起来。